Nitto Denko Avecia to acquire Girindus contract manufacturing business

Nitto Denko Avecia will acquire Girindus America's oligonucleotide and small molecule API contract manufacturing business. Nitto Denko Avecia said the acquisition will allow it to offer customers an expanded range of manufacturing capabilities, as well as a second manufacturing facility for security of supply.
Nitto Denko Avecia

ProBioGen has launched a set of engineered, royalty-free biopharmaceutical CHO production cell lines

ProBioGen

Pharma sales flat for DSM

DSM's pharma business reported net sales growth of 1%. However the company said the results were adversely impacted by an uneven delivery pattern at DSM Pharmaceutical Products and by lower margins at DSM Sinochem Pharmaceutical, despite higher volumes. DSM also said it expected business conditions in pharma to remain challenging for the remainder of the year.
DSM

Kemwell will manufacture biosimilar drugs for Avesthagen

Hindu Business Line

Mixed sales performance at AMRI

AMRI reported a 20% fall in sales to $7.4m for Q3 2012 for its development and small scale manufacturing business. The company reported a 14% rise in sales t $9.3m for large scale manufacturing.
AMRI

Cambrex reported Q3 2012 sales rising 2.8% to $59.8m

Cambrex

Angel Biotechnology has signed a new deal to expand CTX cells and produce the GMP drug substance batch for ReNeuron

The Scotsman

Wacker Biotech will provide its customers with access to XL-protein's PASylation platform for the production of biopharmaceuticals with extended plasma half-lives

Wacker

Cytovance Biologics will develop the process an provide cGMP manufacturing for Fountain BioPharma's monoclonal antibody for the treatment of allergy

Pharmaceutical Business Review

Lonza to cut jobs at Visp

Lonza will cut 400 jobs at its Visp, Switzerland, site and another 100 in global support functions. The company said that its Q3 2012 performance was on-track and reported steady demand resulting in capacity utilisation as expected in both its chemical and biological custom manufacturing.
Business Week

SAFC will provide pre-formulation services for CrystalGenomics next-generation non-steroidal anti-inflammatory drug API

Pharmabiz

Oxford BioMedica has launched OXB Solutions to provide contract manufacturing and development from its Oxford, UK facility

OXB Solutions

Althea Technologies will manufacture circumsporozoite protein for Pfenex using Pfenex's production process

Pfenex

DSM Pharmaceutical Products will provide process development and cGMP manufacture of Paranta Biosciences' lead recombinant human protein at its Brisbane, Australia, facility

Fierce Pharma Manufacturing

Fujifilm Diosynth Biotechnologies and Piramal Healthcare UK will jointly offer seamless contract development and manufacture of antibody drug conjugates

Manufacturing Chemist

The US FDA has approved 28 NMEs to date in 2012

FDA

John Birch has been appointed as a non-executive director at Cobra Biologics

Outsourcing Pharma

Lonza will develop and manufacture OncoMed’s pipeline of anti-cancer stem cell therapeutics at its mammalian manufacturing facility in Slough, UK

GEN

Sigma Aldrich reported a 17% rise in revenues at SAFC to $211m in Q3 driven by a double-digit growth in the custom pharma manufacturing business

Nasdaq

EU confirms API import rules

The European Union (EU) has confirmed its new rules regarding the import of APIs into member states. From 2 Jan 2013 all imported APIs must have been manufactured to an EU-equivalent GMP and by 2 July 2013 the importer will need to request and receive written confirmation of this compliance from the relevant regulatory authority.
Pharma Times

AMRI has extended its supply contract with Shire for a further five years

Pharmaceutical Business Review

Boehringer Ingelheim has resumed manufacturing at its Ben Venue, Ohio, facility

Nasdaq

Sales for Albemarle's fine chemistry business in Q3 2012 were $193.0m up 8% over 2011

Seeking Alpha

Dottikon to expand

Dottikon plans to increase its process development and optimisation capacities by 20% and extend its high-pressure technology in heterogeneous and homogeneous catalysis. The company expects the new capacity to be available in H2 2013. Additionally the company will strengthen and expand its catalysis group, including the development and acquisition of high-pressure parallel screening equipment. The company has terminated its talks with Solvias.
Speciality Chemicals

Ark Therapeutics will manufacture Laurantis Pharma's Lymfactin

Ark Therapeutics

Pharma looks back to the west

Speaking at CPhI Albemarle’s director of fine chemistry services David DeCuir said that the pharma industry is looking back to western suppliers as a result of quality issues, potential interruptions with supplies from Asia and rising costs.
In-pharma Technologist

Recipharm will provide formulations envelopment for Astimex Pharma at its Solna, Sweden, site

Pharmaceutical Business Review

Piramal Healthcare is looking to expand its CRAMS business via acquisitions in the US or Europe

Outsourcing Pharma

Novasep to build commercial scale chromatography plant

Novasep is investing €30m to build a commercial API chromatography plant in Mourenx, France, to address its projected demand for a large volume, highly purified APIs. The company said it expects the facility to be operational within 18 months.
GEN

Lonza will produce induced pluripotent stem cells for the National Institutes of Health Center for Regenerative Medicine in Walkersville, MD

Lonza

BASF will launch a production line for precious metal-based fine chemical catalysts in Mangalore, India

BASF

Dr Reddy's Laboratories has expanded activated mPEG manufacturing and the development and manufacture of APIs at its manufacturing facility in Mirfield, UK

Pharmabiz

Olympus Biotech will provide contract biomanufacturing from its state-of-the-art facility in Lebanon, NH

Outsourcing Pharma

Almac readies API manufacturing expansion

Almac has almost completed the expansion of its API manufacturing facility in Craigavon, UK. The upgraded facility, which will be operational by the end of the year, includes the installation of two 1000L reactors and state-of-the-art pressure filter dryer.
Almac

Almac and DSM to collaborate in biocatalysis

Almac and DSM Pharmaceutical Products will partner their biocatalysis capabilities for the manufacturing of APIs. Almac said its expertise in rapid enzyme identification, scale-up and implementation into early phase projects complements DSM’s experience and track record of over 30 commercial manufacturing bioprocesses run on a multi-ton scale.
Pharmaceutical Business Review

Dalton Pharma Services will provide scale up and manufacture of a conjugate vaccine for tuberculosis developed by the University of Guelph

Research Views

Novasep has appointed Roger-Marc Nicoud as non-executive chairman of the board and Patrick Glaser as president and CEO

Novasep

AMPAC Fine Chemicals has applied to the US Drug Enforcement Administration to be registered as a bulk manufacturer of Tapentadol

Federal Register

Lonza-Teva biosimilar on hold

Teva has suspended its phase III study of a biosimilar of Rituxan, which it os jointly developing with Lonza. Lonza's shares fell as the company said the partners are evaluating how to move forward with testing as the regulatory environment for biosimilars gets more restrictive.
Fierce Biotech and Business Week

Lonza will manufacture of Celladon’s phase IIb-stage targeted enzyme replacement therapy candidate Mydicar for clinical trials

GEN

BASF relocates pharma ingredients to New Jersey

BASF will centralise the management of its Pharma Ingredients and Services business unit in Florham Park, NJ. The unit, which was previously managed from Evionnaz, Switzerland, will be led by Scott Thomson as Senior Vice President. BASF said the relocation of management will not affect the regional business and production units in Europe, including Evionnaz.
New Jersey Star Ledger

SAFC expands in Irvine

SAFC will add a powder manufacturing line at its Irvine, Scotland, facility. The expansion will be supported with a £1.5m grant from Scottish Enterprise and will create 24 new jobs.
St Louis Business Journal

CHP adds capacity

Cedarburg Hauser Pharmaceuticals has expanded its Wisconsin API plant by 50% to meet commercial demand. The company has also added reactor and chiller capacity for GMP cryogenic reactions, made improvements to the air handling systems, installed a reverse osmosis water system, improved isolation capabilities, and upgraded their Emerson DeltaV Digital Automation System.
Cedarburg Hauser Pharmaceuticals

Lonza will develop and manufacture Intellect Neurosciences antibody drug conjugate Conjumab-A

Intellect Neurosciences

Market rumours suggest that BASF or Sabic may be looking to acquire Lonza for around £2.2bn

Lonza

17 Socma member facilities have qualified for the ChemStewards Excellence Tier

Socma

Carbogen Amcis has partnered with ADC Biotechnology to provide customers with seamless development and manufacturing services for antibody drug conjugates

Carbogen Amcis

Gallus BioPharmaceuticals and Roslin Cells will provide manufacturing services cell therapy-based biopharmaceutical products customers

PR Web

India plans to establish a competent authority to meet EU API import requirements from July 2013

In-pharma Technologist

Dishman has licenced statin synthesis technology from Redx Pharma to enhance its CRAMS portfolio

Business Standard

The European Commission has revised its GMP guidelines to align them with ICH Q10

In-pharma Technologist

Navidea blames manufacturer

Navidea Biopharmaceuticals attributed the Complete Response Letter from the US Food and Drug Administration regarding its NDA for Lymphoseek to issues with third-party contract manufacturers. In November 2009, Navidea appointed Reliable Biopharmaceutical Corporation for the manufacture and supply of the API for Lymphoseek. Final product manufacturing including final drug formulation, lyophilization and packaging processes for Lymphoseek is performed by OSO BioPharmaceuticals Manufacturing LLC.
Reuters

Boehringer Ingelheim implements disposable biomanufacturing

Boehringer Ingelheim has implemented single-use biomanufacturing at its mammalian facilities worldwide. The system can incorporate different commercially available single-use systems in 100L and 500L GMP facilities for clinical material supplies or for non-GMP process development.
Biopharmaceutical Business Review

Cambridge Major to add capacity

Cambridge Major Laboratories is to expand its large scale API manufacturing facility in Germantown, WI, as a result of growth in demand. The company will add reactor capacity and isolation equipment. Brian Scanlan, President & CEO of Cambridge Major, said that the company's "invest in the West" policy continues to bear fruit. He added that the company is "very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of API's in later phases of clinical development."
Milwaukee Business Journal

Codexis to cut 133 jobs after deal with Shell terminated

In-pharma Technologist

GE Healthcare has launched a range of modular biomanufacturing facilities

In-pharma Technologist

Piramal Healthcare is rumoured to be in talks to acquire Ind-Swift Laboratories' CRAMS business and facilities

Business Standard

Aesica Partners with University of Bradford

Aesica has partnered with the Centre for Pharmaceutical Engineering Science at the University of Bradford. Aesica will benefit from the University's research facilities and the University will gain access to Aesica's GMP manufacturing facilities.
Manufacturing Chemist

Mike Ironside has been appointed as General Manager, TTC, at Hovione

Hovione

Sales rise for Siegfried in H1

Siegfried reported H1 2012 sales of CHF178.7m up 2.9% on 2011 and profits rose 29% to CHF40.1m. The company said that sales of drug products rose markedly after the launch of new drugs in the first half year, however it's drug substance business passed lower costs for raw materials on to customers.
In-pharma Technologist

Ark to concentrate on contract manufacturing

Ark Therapeutics has announced that it will no longer invest in proprietary drug development, outlicense its development assets and focus on contract manufacturing. The company has attracted some contracts for its viral manufacturing expertise over the last year and recently appointed a new ceo with manufacturing experience. Financial analysts were split on the decision. Canacord Genuity believes that Ark has a substantial opportunity as a partner for companies in viral product development while Nomra Code said that the question remains whether the Ark will be able to attract sufficient manufacturing contracts in the near term to attain profitability of its contract manufacturing services business.
Ark Therapeutics

Angel Biotechnology will develop and manufacture arGentis Pharmaceuticals collagen product for systemic sclerosis

Angel Biotechnology

Conrad Winters has been appointed as Director, Drug Product Development at Hovione

PR Newswire

Carbogen Amcis returns to profit

Dishman reported sales at Carbogen Amcis of $24m for its first quarter. Janmejay R Vyas, chairman and managing director of Dishman Pharma, said that the company has spent 18 months restructuring the Swiss business and that they plan to consolidate in the near future. He expects that Carbogen Amcis will contribute a profit of $7m to Dishman this year.
Business Standard

Boehringer Ingelheim reported sales from biopharmaceutical manufacturing falling from €233m to €214m in H1 2012 in the first half of 2012

Boehringer Ingelheim

New deal for Cambrex leads to expansion

Cambrex will supply phase III and pre-launch quantities an API for an un-named customer. The company expects the agreement to contribute $20m in 2013. In order to meet the demand under the new agreement, Cambrex will invest significant capital over the remainder of 2012 and in early 2013 to expand our multipurpose large scale cGMP assets.
Cambrex

Siegfried Holding will exchange 80,000m2 of land with the City of Zofingen and StWZ Energie AG, and will obtain land bordering its premises for expansion

Siegfried

Ark Therapeutics and EMD Millipore will collaborate to optimise production of viral based bioengineered vaccines and other live viral products for pilot and production scale

Ark Therapeutics

Laureate Biopharma has developed the process and is manufacturing ZZ Biotech's potential therapeutic for ischemic stroke for phase I clinical trials

Laureate Biopharma

Ampac fine chemicals returns to profit

Ampac reported fine chemicals revenues of $36.4m in its Q3 2012 up 18% on 2011, led by strong anti-viral products revenues. The company said its fine chemicals activities returned to profit during the quarter which it attributed to redesigned processes and cost savings initiatives.
Seeking Alpha

Aurobindo Pharma plans to earn 25% of its annual revenues from its custom research and manufacturing business in the next 4-5 years

Economic Times

Gallus BioPharmaceuticals will provide process development and clinical and commercial supply for mammalian cell-based biopharmaceutical products to customers of Theorem Clinical Research

Theorem Clinical Research

Fuji Pharma acquires Thai plant

Fuji Pharma has acquired the Olic pharmaceutical manufacturing plant in Ayutthaya province, Thailand, for $53m from DKSH. Charles Toomey, executive vice-president for healthcare business unit at DKSH, said that contract manufacturing is a non-core competency for DKSH and that Fuji has significant manufacturing expertise.
Bangkok Post

Small sales rise and restructuring at DSM

Sales rose 2% to €182m in Q2 2012 for DSM's pharmaceutical business. The company said that business conditions are likely to remain challenging, although it anticipates that it will make further strategic progress. The company also announced a series of restructuring measures including the termination of biosimilar product development by its Percivia joint venture, which will now focus on the existing PER.C6 technology licensing business.
In-pharma Technologist

Boehringer Ingelheim will manufacture gevokizumab for Xoma and Servier at its Biberach, Germany facility, following the transfer of Xoma's berkeley facility to CMC

GEN

Lonza has licenced the induced pluripotent stem cell (iPSC) patent portfolio from iPS Academia Japan

Lonza

AMRI revenues for development/small scale manufacturing fell 8% to $17.9m for H1 2012, while large scale manufacturing rose 4% to $49.0m

AMRI

Cambrex reported Q2 2012 sales of $77.1m, up 14.3% on 2011

Cambrex

CMC acquires Xoma facility

CMC Biologics has acquired Xoma's large-scale biologics manufacturing operations Berkeley, CA. The 3100m² facility includes three 2750L stainless steel bioreactors and two purification suites. CMC expects to begin offering contract manufacturing services from Berkeley when the transaction closes.
GEN

Archimica has been fined £100,000 for its “abysmal management and incompetent” handling of safety procedure at its Sandycroft, UK, site

North Wales Daily Post

Dottikon has entered exclusive talks to acquire Solvias' synthesis and catalysis business unit in Rosental, Switzerland

Dottikon

Rentschle Biotechnologie will develop packaging cell lines containing a novel vector from Hannover Medical School and to use these commercially for the contract manufacturing of gene therapeutics

Hannover Medical School

Ark Therapeutics will supply manufacturing and development services for a European gene therapy company's therapeutic vaccine product

Ark Therapeutics

Custom manufacturing "firm" for Lonza

Lonza reported H1 revenues increasing to CHF1.9bn. The company said demand in its custom manufacturing business was firm, resulting in capacity utilisation above 75% in both chemical and biological plants, as well as a strong project pipeline. Lonza said it had provided a full response to the FDA regarding the 2011 warning letter received at its Hopkinton, MA, plant and that corrective action had been taken. Looking to the future, the company said it has initiated an investment in formulated products.
Reuters

Dalton Pharma Services provided API development and manufacturing for a Dengue fever clinical trial in Singapore

Dalton

Quarterly record sales for SAFC

Sigma-Aldrich's fine chemicals business, SAFC, reported sales of $223m in Q2, with organic growth of 8% over 2011. Company president and ceo Rakesh Sachdev said "We were pleased by the improved performance of our SAFC custom pharma business, which saw solid growth in cGMP manufactured products in second quarter 2012." Sanchev said the division had double digit sales growth for custom-manufactured high-potency compounds to pharma customers which he attributed to customers recognising the company's investment in HPAPI capacity in Wisconsin.
Seeking Alpha

Piramal Healthcare will change its name to Piramal Enterprises following its increase in business activities

Economic Times

Novasep invests in HPAPI manufacturing

Novasep is investing €3m to expand its highly potent API manufacturing capabilities at its Le Mans, France facility. The expansion will allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies. The new facility will include the capability to perform cryogenic chemistry at -60C in hastelloy reactors. The company will also add large-scale HPLC chromatography and drying in confined areas to manufacture ADC toxins at commercial scale. The plant expansion is expected to be fully operational by the beginning of 2013.
Novasep

ScinoPharm will manufacture topiramate the API for Vivus' Qsymia, approved by the FDA earlier this week

ScinoPharm

Record Q2 for Albemarle's fine chemicals

Albemarle reported record sales in Q2 2012 at $208.7m up 13% on 2011. The company attributed this to favourable volumes and pricing, partly offset by unfavorable foreign currency impacts.
Seeking Alpha

DSM Pharmaceutical Products will provide process development and cGMP manufacture for one of Recepta Biopharma's lead antibodies in Groningen, The Netherlands

Pharmaceutical Business Review

Israel and Switzerland have requested exclusion from the EU's rules for API importation

In-pharma Technologist

Lonza has launched its new GS Xceed Gene Expression System, which it claims will reduce cell line development timelines by up to 6 weeks and can achieve titers of up to 6 g/L

Lonza

Siegfried to build API plant in China

Siegfried, supported by the Chinese development organisation NETDA, will build an API manufacturing plant in Nantong, China. The facility will meet cGMP standards. Siegfried said the site has space for a second phase, which may include finished dosage form production. The new facility is expected to be on-stream in 2014.
Pharmaceutical Business Review

ScinoPharm invests in cytotoxic manufacturing

ScinoPharm will invest $37.6m in the construction of a high potency cytotoxic injectable plant at Tainan Science Park. ScinoPharm said the new facility will include space for R&D, quality control, washing, sterilisation, manufacturing, filling, lyophilisation, packaging, and storage. The company expects the plant to be completed in 2014.
ScinoPharm

Aesica plans to add 100 jobs at its Queensborough, UK, facility

Aesica

Dishman to cancel SEZ project

Dishman is to exit its special economic zone in Ahmedebad, India, and sell the land for $108m. In 2009, Dishman merged its engineering SEZ into its pharma SEZ.
Economic Times

Lonza has extended its XS Technology platformm to two additional microbial systems: pacha pastoris and bacillius subtilis

Lonza

Albemarle expands API capacity

Albemarle has expanded and upgraded its API manufacturing facility in South Haven, MI. The new capacity came online on 1 June. The investment at South Haven matches the solids handling equipment with the reactor capacity and Albemare claims it will enable the company to advance its growing portfolio of custom API products.
In Pharm

Amag moves to contract manufacturing

Amag Pharmaceuticals plans to close its manufacturing facility in Cambridge, MA, and is moving to an outsourced manufacturing model. The company will reduce its workforce by 45 as a result of the disposal.
Aman Pharmaceuticals